https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-august-21-2026/ 2026-08-23T14:21:38Z Pharminent en GLP-1 Competitive Market Digest • Weekly • August 21, 2026 2026-08-23T14:21:36Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-august-21-2026/ 2026-08-21T22:08:22Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • August 21, 2026 2026-08-21T22:08:19Z Blog https://pharminent.com/strategic-news-watch-august-21-2026/ 2026-08-21T21:49:10Z Pharminent en Johnson & Johnson Wins EU Approval for Tecvayli-Daratumumab in Second-Line Myeloma 2026-08-21T21:49:07Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-august-20-2026/ 2026-08-21T21:28:34Z Pharminent en Rare Disease & Gene Therapy Digest • August 20, 2026 2026-08-21T21:28:32Z Blog https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-august-19-2026/ 2026-08-21T21:26:29Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • August 19, 2026 2026-08-21T21:26:25Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-21-2026/ 2026-08-21T21:17:32Z Pharminent en Strategic News Watch • August 21, 2026 2026-08-21T21:17:30Z Blog https://pharminent.com/novo-nordisk-starts-trialing-lower-maintenance-doses-of-oral-wegovy/ 2026-08-23T14:07:40Z Pharminent en Novo Nordisk starts trialing lower maintenance doses of oral Wegovy 2026-08-21T11:44:07Z Blog https://pharminent.com/how-cost-and-perception-could-reshape-the-glp-1-market/ 2026-08-23T14:07:52Z Pharminent en How cost and perception could reshape the GLP-1 market 2026-08-21T11:00:00Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-august-19-2026/ 2026-08-21T10:06:10Z Pharminent en Manufacturing Intelligence • Weekly Digest • August 19, 2026 2026-08-21T10:06:07Z Blog